Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.
作者： A Cull , S Howat , E Greimel , A.-C Waldenstrom , J Arraras
DOI: 10.1016/S0959-8049(00)00369-5
关键词: Disease 、 Abdominal symptoms 、 Physical therapy 、 Ovarian cancer 、 Cancer 、 Clinical trial 、 Gynecology 、 Chemotherapy 、 Medicine 、 Sexual functioning 、 Quality of life
摘要: A questionnaire was developed, according to the European Organization for Research and Treatment of Cancer (EORTC) published guidelines, supplement EORTC quality life questionnaire-core 30 (QLQ-C30) assess (QL) women with ovarian cancer treated in clinical trials. The provisional 28-item module, OV28, assesses abdominal symptoms; peripheral neuropathy; other chemotherapy side-effects; hormonal body image; attitude disease treatment; sexual functioning. first 24 items module (excluding functioning) were included a UK multicentre trial (SCOTROC). data used preliminary scaling analysis. Two problematic identified. When these as single along 'other side-effects' instrument showed excellent scale properties. Mean scores discriminated between patients pre- on chemotherapy. This is promising tool assessing QL cancer. international field study (Protocol 15982) more fully psychometric properties OV28 well underway.
elsevier.com
sci-hub.se 参考文章(28)
J Dancey, B Zee, D Osoba, M Whitehead, F Lu, L Kaizer, J Latreille, JL Pater, Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy Quality of Life Research. ,vol. 6, pp. 151- 158 ,(1997) , 10.1023/A:1026442201191
M. Groenvold, J. Blazeby, M.A.G. Sprangers, K. Bjordal, A. Cull, N.K. Aaronson, The European organization for research and treatment of cancer approach to developing questionnaire modules: an update and overview Quality of Life Research. ,vol. 7, pp. 291- 300 ,(1998) , 10.1023/A:1024977728719
Philip Bonomi, Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Seminars in Oncology. ,vol. 29, pp. 78- 86 ,(2002) , 10.1053/SONC.2002.31528
Peter E. Schwartz, Thomas J. Rutherford, Joseph T. Chambers, Ernest I. Kohorn, Robert P. Thiel, Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: Long-Term Survival Gynecologic Oncology. ,vol. 72, pp. 93- 99 ,(1999) , 10.1006/GYNO.1998.5236
D. Osoba, B. Zee, J. Pater, D. Warr, L. Kaizer, J. Latreille, Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Quality of Life Research. ,vol. 3, pp. 353- 364 ,(1994) , 10.1007/BF00451727
Alan Coates, Val Gebski, James F. Bishop, Peter N. Jeal, Robert L. Woods, Raymond Snyder, Martin H.N. Tattersall, Michael Byrne, Vernon Harvey, Grantley Gill, John Simpson, Roslyn Drummond, Judy Browne, Rodney van Cooten, John F. Forbes, , Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. The New England Journal of Medicine. ,vol. 317, pp. 1490- 1495 ,(1987) , 10.1056/NEJM198712103172402
A. Coates, F. Porzsolt, D. Osoba, Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy European Journal of Cancer. ,vol. 33, pp. 1025- 1030 ,(1997) , 10.1016/S0959-8049(97)00049-X
Amita Patnaik, Catherine Doyle, Amit M Oza, Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Anti-Cancer Drugs. ,vol. 9, pp. 869- 878 ,(1998) , 10.1097/00001813-199811000-00006
Ali Montazeri, James McEwen, Charles R. Gillis, Quality of life in patients with ovarian cancer: current state of research. Supportive Care in Cancer. ,vol. 4, pp. 169- 179 ,(1996) , 10.1007/BF01682336
D Osoba, What has been learned from measuring health-related quality of life in clinical oncology. European Journal of Cancer. ,vol. 35, pp. 1565- 1570 ,(1999) , 10.1016/S0959-8049(99)00192-6